Harmony Gold Mining reports 61% operating profit surge but output decline and copper capex weigh on HMY stock
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
Read More 6 minute read Pharma Industry News Why predictive biomarkers may determine ALX Oncology’s competitive viability in HER2-positive breast cancer Find out why CD47 biomarkers could determine ALX Oncology’s ability to compete in HER2-positive breast cancer and what risks remain for evorpacept. bySoujanya RaviFebruary 3, 2026